Royalty Report: Drugs, Disease, Alzheimer’s disease – Collection: 269747

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Disease
  • Alzheimer’s disease
  • Stroke treatment
  • cardiac
  • Therapeutic
  • Nerve
  • Diagnostic
  • Central Nervous System
  • Medical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 269747

License Grant
The University has granted a world-wide right and exclusive license, with the right to grant sublicenses, under certain patent rights and related technology.
License Property
The licensed property is for the use of bryostatin structural derivatives, known as bryologs.

Bryostatin is a drug targeting the activation of Protein Kinase C epsilon.

Field of Use
This license is for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury.  Bryostatin is used for the treatment of Alzheimer’s disease.

IPSCIO Record ID: 376935

License Grant
University has granted to the Licensee a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of bryostatin structural derivatives, known as “bryologs,” for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury, for the life of the licensed patents. The Licensee is required to use commercially reasonable efforts to develop, manufacture and sell products (Licensed Products) in the Licensed Field of Use (as defined) during the term of the licensing agreement which expires upon the termination of the last valid claim of any licensed patent under this agreement.
License Property
Bryostatin structural derivatives, known as “bryologs' is an active pharmaceutical ingredient to be used in a drug product.
Field of Use
Field of use is for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury.

IPSCIO Record ID: 378825

License Grant
University has granted to the Licensee a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of “Bryostatin Compounds and Methods of Preparing the Same,” or synthesized bryostatin, for use in the treatment of neurological diseases, cognitive dysfunction and psychiatric disorders, for the life of the licensed patents.
License Property
Bryostatin structural derivatives, known as “bryologs' is an active pharmaceutical ingredient to be used in a drug product.
Field of Use
Field of use is for use in the treatment of neurological diseases, cognitive dysfunction and psychiatric disorders.

IPSCIO Record ID: 212736

License Grant
Pursuant to which University has granted to the Company a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under certain patent rights and related technology for the use of “Bryostatin Compounds and Methods of Preparing the Same,” or synthesized bryostatin, for use in the treatment of neurological diseases, cognitive dysfunction and psychiatric disorders, for the life of the licensed patents.
License Property
Bryostatins are a group of macrolide lactones isolated from the marine organism, Bugula neritina. Bryostatins are potent modulators of protein kinase C,

The technology relates to bryostatin, for use in the treatment of neurological diseases, cognitive dysfunction and psychiatric disorders.

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 248095

License Grant
The License Agreement, between the Licensor and the Swedish Licensee, is hereby amended so as to remove any Co-Promote rights for Licensor for any Licensed Product.

With this amendment between the Swedish Licensor and Licensee, the License Agreement is amended to remove Licensors right of first negotiation with respect to the development, manufacture or sale of any substance or product outside the Field but falling within the Central Nervous System (CNS) research area, and,  and all licenses to Licensor in the License Agreement related to products in the Field relating to AP are hereby terminated.

License Property
The compounds relate to the Alzheimers Project and Stroke Project.

Alzheimers Project Licensed Product means a product incorporating as an active ingredient a compound which is a spin trapping agent, derivative or composition thereof used as a free radical scavenger, for the treatment of Alzheimers disease.

Stroke Project Licensed Product, including a compound known as NXY-059 means a product incorporating as an active ingredient a compound based upon using spin trapping agents and derivatives and compositions thereof as free radical scavengers, for acute treatment of stroke, and, prophylactic treatment of stroke, head trauma, multi-infarct dementia, and pain associated with stroke, as further specified in the R&D Plans.

Field of Use
The stroke project is used as free radical scavengers and/or therapeutics for acute treatment of stroke, prophylactic treatment of stroke, head trauma, multi-infarct dementia, and pain associated with stroke, as further specified in the R&D Plans.

IPSCIO Record ID: 240607

License Grant
The License Agreement, between the Licensor and the Swedish Licensee, is hereby amended so as to remove any Co-Promote rights for Licensor for any Licensed Product.
License Property
The compounds relate to the Alzheimers Project and Stroke Project.

Alzheimers Project Licensed Product means a product incorporating as an active ingredient a compound which is a spin trapping agent, derivative or composition thereof used as a free radical scavenger, for the treatment of Alzheimers disease.

Stroke Project Licensed Product, including a compound known as NXY-059 means a product incorporating as an active ingredient a compound based upon using spin trapping agents and
derivatives and compositions thereof as free radical scavengers, for acute treatment of stroke, and, prophylactic treatment of stroke, head trauma, multi-infarct dementia, and pain associated with stroke, as further specified in the R&D Plans.

Field of Use
The stroke project is used as free radical scavengers and/or therapeutics for acute treatment of stroke, prophylactic treatment of stroke, head trauma, multi-infarct dementia, and pain associated with stroke, as further specified in the R&D Plans.

IPSCIO Record ID: 307771

License Grant
Medical School granted Licensee (a) a revenue-bearing, world-wide right and exclusive license, with the right to grant sublicenses (on certain conditions), under the Medical School’s interest in certain joint patents held by the Company and the Medical School (the Joint Patents) as well as in certain results and data (the Data Package”) and (b) a non-exclusive license, with the right to grant sublicenses on certain conditions, to certain technical information, both relating to the diagnostic, prophylactic or therapeutic use for treating diseases or disorders in humans relying on activation of Protein Kinase C Epsilon (PKCe), which includes Niemann-Pick Disease (the Medical Schools Field of Use). This Agreement allows Licensee to research, discover, develop, make, have made, use, have used, import, lease, sell, have sold and offer certain products, processes or methods that are covered by valid claims of the Medical School’s interest in the Joint Patents or an Orphan Drug Designation Application covering the Data Package (Medical Schools Licensed Products) in the Medical School Field of Use (as such terms are defined in this Agreement).
License Property
Protein Kinase C Epsilon (PKCe) relates to the diagnostic, prophylactic or therapeutic use for treating diseases or disorders in humans.

Medical Schools focus is on medical and scientific training, biomedical research, and patient care.

Field of Use
The Field of Use is for the treatment of diseases or disorders in humans which includes Niemann-Pick Disease. This is a rare progressive genetic disorder characterized by an inability of the body to transport cholesterol and other fatty substances (lipids) inside of cells. This leads to the abnormal accumulation of these substances within various tissues of the body, including brain tissue.

Licensee is a biopharmaceutical company focused on developing a product platform based upon a drug candidate called bryostatin for the treatment neurodegenerative or cognitive diseases and dysfunctions, such as Niemann-Pick Disease.

IPSCIO Record ID: 336372

License Grant
Canadian Licensor hereby grants to Licensee a license to Licensor’s intellectual property rights in the Reagents and the POC Rapid Assays to manufacture the POC Rapid Assays in accordance with the POC Rapid Assay Specifications, subject to the terms and conditions of this Agreement, for the sole and exclusive purpose of incorporating the Reagents into P~C Rapid Assays.
License Property
Licensor has developed, and is in the process of further developing, certain unique, proprietary biomarkers and protein targets for the diagnosis of congestive heart failure, insulin resistance, Alzheimer’s disease, traumatic brain injury and other various diseases, excluding stroke.

Reagents shall mean biomarkers and protein targets developed and produced by Licensor for the diagnosis of congestive heart failure, insulin resistance, Alzheimer’s disease, traumatic brain injury and other various diseases, excluding stroke. The term “Reagents” shall also include all other biomarkers and protein targets developed and produced by Licensor (other than for stroke) for which there shall be application in the point of care diagnostic products.

POC Rapid Assays shall mean rapid assay diagnostic point of care products, utilizing Reagents; provided, however, that “POC Rapid Assays” shall not include devices for test procedures performed in a hospital’s central clinical laboratory or in a reference laboratory setting. In addition, “POC Rapid Assays” shall not include any assay that can be used on any instrument with random access capability and/or any instrument with the ability to analyze multiple samples.

POC Rapid Assay Specifications shall mean the standards and specifications for the manufacture of the POC Rapid Assays, as developed and agreed to by the Parties, as amended from time to time, and shall be appended to and form part of this Agreement.

Reagent Specifications shall mean the standards and specifications for the manufacture of the Reagents, as developed and agreed to by the Parties, as amended from time to time, and shall be appended to and form part of this Agreement.

Field of Use
The biomarkers are used to determine the diagnosis of congestive heart failure, insulin resistance, Alzheimer’s disease, traumatic brain injury and other various diseases, excluding stroke.  Biomarkers can be measured through a blood sample.

IPSCIO Record ID: 279383

License Grant
The Israeli Licensor grants an exclusive, even as to Licensor, worldwide license, with the right to sublicense through multiple tiers of sublicense, under the Licensed Technology and Research Technology to research, develop, make, have made, use, sell, offer for sale, have sold and import Licensed Products and Additional Products in the Field.
License Property
The research is for Novel compounds for treatment and as Disease-modifying agents in alzheimers and related CNS & PNS Diseases.

The patents relate to AF150(S) and Congeners, and, AF267B and Congeners, and, AF292 and Congeners.

Licensed Compound shall mean the compound known as AF292 and its isomers, salts, esters and derivatives.

The central nervous system (CNS) is the part of the nervous system consisting of the brain and spinal cord. The peripheral nervous system (PNS) is one of two components that make up the nervous system of bilateral animals, with the other part being the central nervous system (CNS).

Field of Use
The Field shall mean all therapeutic uses.  The compounds for patented drugs are for treatment, prevention and/or diagnosis of nervous system disorders.

License relates to muscarinic agonist assets including its lead drug candidate for Alzheimer’s Disease, or AD, NGX267, and NGX292.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.